Bone Biologics Corp (BBLG) - Total Liabilities
Based on the latest financial reports, Bone Biologics Corp (BBLG) has total liabilities worth $418.59K USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Bone Biologics Corp (BBLG) equity growth momentum to track the company's year-over-year net asset growth rate.
Bone Biologics Corp - Total Liabilities Trend (2012–2025)
This chart illustrates how Bone Biologics Corp's total liabilities have evolved over time, based on quarterly financial data.
Bone Biologics Corp Competitors by Total Liabilities
The table below lists competitors of Bone Biologics Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CBEYOND
F:C5B
|
Germany | €400.03K |
|
ExpreS2ion Biotech Holding AB
ST:EXPRS2
|
Sweden | Skr23.98 Million |
|
Central China Real Estate Limited
F:AJ5
|
Germany | €103.47 Billion |
|
BlackRock Latin American Investment Trust plc
LSE:BRLA
|
UK | GBX824.00K |
|
Labrador Technologies Inc
V:LTX
|
Canada | CA$1.24 Million |
|
Biosergen AS
ST:BIOSGN
|
Sweden | Skr13.04 Million |
|
Avinger Inc
NASDAQ:AVGR
|
USA | $9.73 Million |
|
Australian Bond Exchange Holdings Ltd
AU:ABE
|
Australia | AU$6.83 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Bone Biologics Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BBLG market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bone Biologics Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bone Biologics Corp (2012–2025)
The table below shows the annual total liabilities of Bone Biologics Corp from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $418.59K | +10.82% |
| 2024-12-31 | $377.71K | -54.57% |
| 2023-12-31 | $831.40K | -67.37% |
| 2022-12-31 | $2.55 Million | +2450.25% |
| 2021-12-31 | $99.91K | -99.27% |
| 2020-12-31 | $13.69 Million | +15.08% |
| 2019-12-31 | $11.90 Million | +23.44% |
| 2018-12-31 | $9.64 Million | +4.87% |
| 2017-12-31 | $9.19 Million | -4.33% |
| 2016-12-31 | $9.61 Million | +23.78% |
| 2015-12-31 | $7.76 Million | +3.21% |
| 2014-12-31 | $7.52 Million | +32.03% |
| 2013-12-31 | $5.70 Million | +121648.85% |
| 2012-12-31 | $4.68K | -- |
About Bone Biologics Corp
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, a… Read more